on MONDAY, CryoLife, Inc. (NYSE: CRY) noted a down move of -1.87% in most recent trading session with finishing price of $24.64. The company negotiated 175058 shares compared to an average volume of 217.69K shares. EPS growth for this year is -184.50% and EPS growth for next year is estimated to reach at 37.59%. EPS growth in past five years was -16.50% while EPS growth in next five years is projected to arrive at 30.00%. Sales growth past 5 years was measured at 13.30%.
CryoLife, Inc. (CRY) reported recently its financial results for the third quarter ended September 30, 2019.
Third Quarter 2019 Financial Results
Total revenues for the third quarter of 2019 were $67.9M, reflecting growth of 5%, and 6% on a non-GAAP constant currency basis, both contrast to the third quarter of 2018. The increase was driven by revenue growth from On-X, JOTEC, and tissue processing.
Net loss for the third quarter of 2019 was ($134,000), or $0.00 per fully diluted ordinary share, contrast to a net income of $1.6M, or $0.04 per fully diluted ordinary share for the third quarter of 2018. Net loss for the third quarter of 2019 includes $1.2M in business development expenses. Non-GAAP net income for the third quarter of 2019 was $2.2M, or $0.06 per fully diluted ordinary share, contrast to non-GAAP net income of $3.1M, or $0.08 per fully diluted ordinary share for the third quarter of 2018.
2019 Financial Outlook
CryoLife expects total revenues for 2019 to be in the range of $276.5M to $278.5M. This compares to the previous predictable range of $280.0M to $284.0M for the year, with the change Because of the effects of foreign currency and a lack of availability of TMR handpieces in the fourth quarter of 2019. Non-GAAP earnings per share are still predictable to be between $0.28 and $0.32 for the full year.
All numbers are presented on a GAAP basis except where expressly referenced as non-GAAP. The Company does not provide GAAP income per ordinary share on a forward-looking basis because the Company is unable to predict with reasonable certainty business development and acquisition-related expenses, purchase accounting fair value adjustments, and any unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP.
CRY added at 3.81% from 20-Days Simple Moving Average, plunged at -2.65% from 50-Days Simple Moving Average and settled at -12.38% from 200 Days Simple Moving Average. The Company has 37.5 million shares outstanding and 36.06 million shares were floated in market. The short ratio in the company’s stock is documented at 4.21 and the short float is around of 2.54%. The average true range of the stock is observed at 0.79 and the relative strength index of the stock is recorded at 51.16.